PEG-MGF
aka PEGylated Mechano Growth Factor
Mechanism
PEG-MGF is the pegylated form of Mechano Growth Factor (MGF), the distinct 24-amino-acid C-terminal E-peptide encoded by the IGF-1Ec splice variant (IGF-1Eb in rodents) that is transiently upregulated in muscle after mechanical loading or damage. MGF is related to but pharmacologically distinct from mature IGF-1 and IGF-1 LR3. Pegylation extends its half-life from minutes to several hours, and the compound is marketed as a research chemical for muscle repair protocols. It is not FDA-approved for any indication.
Identification
| Sequence | YQPPSTNKNTKSQRRKGSTFEERK |
|---|---|
| Typical dose | 200–400 mcg subcutaneous, 2–3x per week |
| Half-life | ~48–72 hours (vs. ~5–7 minutes for unmodified MGF) |
Vendors selling PEG-MGF
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Moglabs | 2 mg | $40.00 | — | 96 |
| BioLongevity Labs | 5 mg | $94.97 | — | 96 |
| Ion Peptide | 2 mg | $39.00 | — | 95 |
| Peptide Tech | 2 mg | $33.99 | — | 94 |
| Peptidology | 5 mg | $87.00 | — | 89 |
| Qihang Peptide | — | — | — | 87 |
| Simple Peptide | 2 mg | $39.00 | — | 85 |
| Peptidegurus | 5 mg | — | — | 84 |
| Crystal Peptides | 2 mg | $49.00 | — | 66 |
| Peptiatlas | — | — | — | 51 |
| HongDa Peptide | — | $91.00 | — | 43 |
| MJT peptides | 2 mg | $97.00 | — | 39 |
| Biotech Peptides | 5 mg | $79.00 | — | — |
| Core Peptides | 5 mg | $63.00 | — | — |
| Flawless Compounds | — | — | — | — |
| Genetic Peptide | 2 mg | $50.00 | — | — |
| Genetic Peptide | 5 mg | $50.00 | — | — |
| Paramount Peptides | 5 mg | $89.00 | — | — |
Research
Performance-enhancing drugs (PEDs) marketed as "research compounds" include unregulated peptides intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.
source →The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
source →This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
source →Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events
source →We examine a gas-phase approach for converting a subset of amino acid residues in polypeptide cations to dehydroalanine (Dha). Subsequent activation of the modified polypeptide ions gives rise to specific cleavage N-terminal to the Dha residue.
source →This study aims to explore the optimal dose of pegylated recombinant human growth hormone (PEG-rhGH) injection to treat children of Turner syndrome (TS), preliminarily evaluate its safety and efficacy and provide scientific and reliable evidence for the medication dosage in Phase 3 clinical trial.
source →The study was evaluated as the optimal dose for the treatment of SGA short stature children by Pegylated Somatropin, initially evaluated its efficiency and safety for the treatment of SGA short stature children and provided scientific, reliable basis for phase III clinical trials for dose selection.
source →Neurodegeneration is characterized by progressive loss of structure and function of neurons. Several therapeutic methods and drugs are available to alleviate the symptoms of these diseases.
source →Primary Objective: * To demonstrate the superior efficacy (composite of all-cause death + Myocardial Infarction (MI)) of Otamixaban to Unfractionated Heparin (UFH) + Eptifibatide Secondary Objectives: * To demonstrate the superior efficacy (composite of all-cause death + MI + any stroke) of Otamixaban as compared to UF…
source →The purpose of this clinical research study is to determine whether apixaban is more effective than acetylsalicylic acid in the prevention of strokes associated with patients with atrial fibrillation. The safety of this treatment will also be studied.
source →This study will assess the efficacy of 8 months treatment of Sandostatin® LAR® High Dose monotherapy or Sandostatin® LAR® High Dose in combination either with growth hormone antagonist or dopamine agonist to control biochemical parameters (GH and insulin-like growth factor I \[IGF I\]) of acromegalic patients not achie…
source →